Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of INZ-701, an
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy, for
the treatment of ENPP1 Deficiency (including Generalized Arterial Calcification of Infancy
Type 1 [GACI] and Autosomal Recessive Hypophosphatemic Rickets Type 2 [ARHR2]).